Bioline RX (BLRX) Earns Coverage Optimism Score of 0.16
News articles about Bioline RX (NASDAQ:BLRX) have been trending somewhat positive this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bioline RX earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.7257345694436 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Bioline RX (BLRX) opened at $1.05 on Friday. Bioline RX has a 12-month low of $0.80 and a 12-month high of $1.38.
Several research firms have commented on BLRX. Zacks Investment Research raised Bioline RX from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research report on Tuesday, October 3rd. HC Wainwright reaffirmed a “buy” rating on shares of Bioline RX in a research report on Tuesday, September 26th. Oppenheimer set a $3.00 price target on Bioline RX and gave the stock a “buy” rating in a research report on Wednesday, October 18th. Maxim Group set a $3.00 price target on Bioline RX and gave the stock a “buy” rating in a research report on Monday, December 4th. Finally, ValuEngine raised Bioline RX from a “strong sell” rating to a “sell” rating in a research report on Thursday, November 30th. Two research analysts have rated the stock with a sell rating and five have given a buy rating to the stock. Bioline RX has a consensus rating of “Hold” and a consensus price target of $2.88.
Bioline RX Company Profile
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Ratings for Bioline RX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioline RX and related companies with MarketBeat.com's FREE daily email newsletter.